about
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesDiagnosis and management of paroxysmal nocturnal hemoglobinuriaIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaA genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemiaTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.Diagnostic criteria for monoclonal B-cell lymphocytosis.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapProtection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model.Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.Alemtuzumab therapy in B-cell lymphoproliferative disorders.Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients.Immune-mediated hemolytic anemia.The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients.Minimal residual disease and survival in chronic lymphocytic leukemia.Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide,Beyond detectable minimal residual disease in chronic lymphocytic leukemia.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaMinimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.Minimal residual disease assessment in chronic lymphocytic leukaemia.
P50
Q24616084-16A8CD36-81D7-4ECE-96A0-BBAD5C7DD138Q24670119-30CAC9B2-1227-44A4-8E79-8BB9B4326FE5Q28306347-857FC08E-DBE8-431C-911C-93A87075D610Q28943555-4C0D15EE-804C-45A1-826C-63F7679D9A78Q33342242-251AF5FB-4B92-4222-82EA-31134485819EQ33377654-DD2D1816-140E-451F-82DC-46AB02600A02Q33396918-6A3B9572-C065-47CA-8CC6-4E0F242506ABQ33419843-D1C9EDEA-452E-4BED-B098-ECE36B741122Q33429161-0B220F09-155E-4400-88EF-0A23D297062DQ33558763-EF26DA3B-7AEF-4D7F-86AA-98449A72493BQ33988895-AF0EB61D-2BA1-461E-95F4-AA05049BC4ACQ34052075-FFB0D8BB-E9A1-47C1-9D1F-9AC99C2420D0Q34136266-452917A9-C2D2-4422-9155-E7F8CF0E6B12Q34219091-61837E7B-B07B-4D16-B234-185EA583D2D5Q34409133-E6B7D795-65C8-47AC-8B97-E3F0207654A5Q34429673-DCD3D0DB-5F0E-4641-8B35-C1BB83CF24B6Q34433926-CFFD046B-383B-40B4-9292-36C8A7966362Q34472100-AF1CEDB9-6E10-4722-B2CC-21724AE58905Q34567835-0F74EE70-424C-44CF-8828-46316E38E267Q34617307-AD5DCA74-89DA-4A9E-850E-B00D0CFD6E62Q34785892-765EF600-30C7-41F0-83A7-E25C59AE533DQ34805491-4F69F09E-179A-422B-9716-7E4F995584DBQ34997368-0F538A01-CE6E-48F7-99C8-411B8061A931Q35123154-266A5EA2-5B70-461D-B7C0-6D4BE646C564Q35206362-CC322CF7-B5A1-4E8C-9323-7217DE7CF582Q35712438-29A780AC-12BD-4553-A734-6889453E1564Q35744056-F6341843-0E08-482B-ADAF-E6B0B7D0EA6EQ35843268-1C26DE25-A780-4A0D-8CF1-5D32EE200BE3Q35961762-F66228EA-8841-42A2-9B6B-B5A8F85E6FF4Q36108937-B64ABCAE-A2BC-464E-9F3C-1048141C2851Q36259026-2D685C20-CFB9-4750-B212-9646F6A1659FQ36285608-D7982F3A-D552-438D-B02E-22AE7E6F6209Q36408990-2A39D5B7-6670-46CC-9C75-7E2C0EE27276Q36486477-48B9F96F-D691-4A8C-9C18-20E0959D1B3BQ36490049-21B57808-02EC-4CE1-ACB8-6A983DABD118Q36665330-99820785-F550-4BF8-8E75-68BEB816DE55Q36780187-070A05F5-F00E-4663-B6E2-5BCDBD9CEDD0Q36840839-94E8BB58-4070-4187-AF8E-041EDB389E8CQ36888218-D279C8F0-C8D6-4933-8857-E51776AA26D5Q36914093-2FCD034B-CE72-4DBD-B0C5-8479978C2569
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
ricercatore
@it
հետազոտող
@hy
name
Peter Hillmen
@ast
Peter Hillmen
@cy
Peter Hillmen
@en
Peter Hillmen
@en-gb
Peter Hillmen
@es
Peter Hillmen
@nl
Peter Hillmen
@sl
type
label
Peter Hillmen
@ast
Peter Hillmen
@cy
Peter Hillmen
@en
Peter Hillmen
@en-gb
Peter Hillmen
@es
Peter Hillmen
@nl
Peter Hillmen
@sl
prefLabel
Peter Hillmen
@ast
Peter Hillmen
@cy
Peter Hillmen
@en
Peter Hillmen
@en-gb
Peter Hillmen
@es
Peter Hillmen
@nl
Peter Hillmen
@sl
P214
P106
P21
P214
P31
P496
0000-0001-5617-4403
P735
P7859
lccn-nb2005011660